Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — NASDAQ OMX & Oppenheimer 14th Annual Israeli Equities Conference (February 2010)
23 slides from Teva Pharmaceutical Industries's conference presentation, Feb 24, 2010
Slide 1: NASDAQ OMX & Oppenheimer 14th Annual Israeli Equities Conference
1 NASDAQ OMX & Oppenheimer 14th Annual Israeli Equities Conference Eyal Desheh, Chief Financial Officer February 24, 2010
Slide 2: Forward looking statements
Forward looking statements 2 TODAY’S PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS, INCLUDING, AMONG OTHER THINGS, REGARDING OUR EXPECTED PROFITABLE GROWTH, REVENUES, NET INCOME, THE DRIVERS AND CONTRIBUTORS OF THIS GROWTH, STRATEGY AND COMPETITIVE ADVANTAGES, WHICH EXPRESS THE CURRENT BELIEFS AN
Slide 3: 2009 Highlights; 2015 Strategy Update
3 2009 HIGHLIGHTS 2015 STRATEGY UPDATE
Slide 4: 2 fundamental questions/topics
2 fundamental questions/topics 4 2009 HIGHLIGHTS 2015 STRATEGY UPDATE
Slide 5: 2009 – strong results
2009 – strong results 5 2008* 2009* Change Sales 11,085 13,899 +25% $m Operating income 2,856 3,853 +35% $m Net income 2,493 3,029 +22% $m EPS 3.03 3.37 +11% $ Cash flow from operations 3,231 3,373 +4% $m * Net income, operating income and EPS are non GAAP results
Slide 6: 2009 – an extraordinary year
2009 – an extraordinary year 6 Record Record sales Financial Record profit levels: gross, operating and net Results Balance Record sales year 2008: an extraordinary in all geographies Business Record sales in all business lines Model Enhancing Copaxone® – solidify position as #1 MS treatment Branded
Slide 7: Excellent margins
Excellent margins 7 2008* 2009* Change Sales 11,085 13,899 +25% $m Operating income 2,856 3,853 +35% $m Net income 2,493 3,029 +22% $m Gross margin 55.3 58.4 % Operating margin 25.8 27.7 % Net margin 22.1 21.8 % * Operating income, net income, gross margin, operating market and net margin are non GA
Slide 8: Continuous growth track record
Continuous growth track record 8 Revenues, $ million CAGR 13,899 +21.5% 2,043 +23.7% 11,085 9,408 1,696 3,271 +11.2% International 1,335 2,976 Europe 2,645 North America 8,585 +25.7% 6,413 5,428 2007 2008 2009
Slide 9: 2009 – balanced business model
2009 – balanced business model 9 By business line By geography $13.9bn $13.9bn International Branded Europe Generic North America
Slide 10: Q4 2009 – exchange rate effect
Q4 2009 – exchange rate effect 10 $ million Q4 Q4 FX Real Growth 2009 2008 effect growth Total sales 3,802 2,848 +33% +98 +30% Operating profit 1,049 746 +41% +1 +40% North America 2,324 1,727 +35% +15 +34% Europe 925 710 +30% +75 +20% International 553 411 +35% +8 +33%
Slide 11: 2009 – exchange rate effect
2009 – exchange rate effect 11 $ million FX Real 2009 2008 Growth effect growth Total sales 13,899 11,085 +25% -572 +31% Operating profit 3,853 2,856 +35% -37 +36% North America 8,585 6,413 +34% -24 +34% Europe 3,271 2,976 +10% -352 +22% International 2,043 1,696 +20% -196 +32%
Slide 12: Quarterly cash flow
Quarterly cash flow 12 $ million 1,025 Cash from operations 969 957 Net asset purchase 195 179 179 733 Dividends distributed 90 126 658 141 136 148 127 134 Free cash flow 700 704 637 470 376 Q4 2008 Q1 2009 Q2 2009 Q3 2009 Q4 2009
Slide 13: Annual cash flow
Annual cash flow 13 $ million 3,373 3,231 658 620 388 528 Cash from operations 1,813 Net asset purchase 501 Dividends distributed 299 2,223 2187 1,013 Free cash flow 2007 2008 2009
Slide 14: Consolidated balance sheet
Consolidated balance sheet 14 31 December, FY, $bn ASSETS 2008 2009 LIABILITIES 2008 2009 Cash & marketable securities 2.0 2.5 ST & LT financial debt 8.4 5.6 Inventories, A/R & other assets 9.5 9.9 SR&A, A/P & other accruals 5.6 6.3 Long-term assets 4.5 4.7 Long-term liabilities 2.5 2.6 Intangible a
Slide 15: Improved financial leverage
Improved financial leverage 15 $ bn 24.8 24.5 24.5 25.1 24.8 5.8 5.6 Debt 8.4 6.7 8.4 17.8 19.3 19.2 Equity 16.4 16.1 Dec Mar Jun Sep Dec 08 09 09 09 09 Leverage 34% 34% 27% 23% 23%
Slide 16: 2010 guidance
2010 guidance 16 Net sales around $16 billion Non-GAAP EPS between $4.40 – $4.60 Significant variance between Q1’2010 and rest of year
Slide 17: 2 Fundamental questions/topics
2 Fundamental questions/topics 17 2009 HIGHLIGHTS 2015 STRATEGY UPDATE
Slide 18: Targets for 2015
Targets for 2015 18 Revenues $31 bn Net income $6.8 bn Net profitability 22%
Slide 19: Maintaining Teva's mix of generics & branded
Maintaining Teva’s mix of generics & branded 19 $31bn ~30% $13.9bn Branded 30% ~70% Generics 70% 2009 2015
Slide 20: Growth through market share
Growth through market share 20 2015 sales 2009-2015 targets CAGR North America $15bn 9.5% Europe $9bn 18.6% International $7bn 23.2% Total $31bn 14.3%
Slide 21: Diversity across business units, products, geographies
Balance between high-growth generics & 21 higher-margin branded business ~30% branded High ~70% Higher GROWTH generic MARGINS Diversity across: BUSINESS UNITS, PRODUCTS, GEOGRAPHIES
Slide 22: Teva 2010-2015: value creation
Teva 2010-2015: value creation 22 9 Growth 9 High profitability Sustainable, 9 balanced business model 9 Financial strength
Slide 23: Teva Pharmaceutical Industries Ltd
tA! TEVA PHARMACEUTICAL INDUSTRIES LTD,